Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Formoterol Fumarate Hydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients
Details : Formoterol Fumarate Hydrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bronchitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : Formoterol Fumarate Hydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLIM
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trials to Assess the Efficacy and Safety of HLIM
Details : HLIM is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 01, 2019
Lead Product(s) : HLIM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRIC
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects
Details : PRIC is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 01, 2019
Lead Product(s) : PRIC
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SA09012
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of SA09012 in Asthma
Details : SA09012 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 04, 2012
Lead Product(s) : SA09012
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pranlukast Hydrate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pranlukast Hydrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Perennial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2012
Lead Product(s) : Pranlukast Hydrate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
